CAR T cell therapy

Mocravimod as an adjunctive treatment to CAR-T cell therapy

CAR-T technology provides engineered patient T cells that target specific markers on tumor cells, such as CD19 or CD20.

Mocravimod as an adjunctive immune treatment to CAR-T cell therapy improves the activation and killing potential of CAR-T cells, reduces the inflammatory cytokine side effects caused by the CAR-T cell therapy and exerts a direct anti-cancer cell effect.

The potential of mocravimod is to enhance the longevity of of CAR-T cell efficacy and to lower cytokine release syndrome (CRS) associated with CAR-T treatments.